Standard

Decline of HIV antigen levels in cerebrospinal fluid during treatment with low-dose zidovudine. / de Gans, J.; Lange, J. M.; Derix, M. M. et al.

In: AIDS (London, England), Vol. 2, No. 1, 1988, p. 37-40.

Research output: Contribution to journal › Article › Academic › peer-review

Harvard

de Gans, J, Lange, JM, Derix, MM, de Wolf, F, Eeftinck Schattenkerk, JK, Danner, SA, Ongerboer de Visser, BW, Cload, P & Goudsmit, J 1988, 'Decline of HIV antigen levels in cerebrospinal fluid during treatment with low-dose zidovudine', AIDS (London, England), vol. 2, no. 1, pp. 37-40. https://doi.org/10.1097/00002030-198802000-00006

APA

de Gans, J., Lange, J. M., Derix, M. M., de Wolf, F., Eeftinck Schattenkerk, J. K., Danner, S. A., Ongerboer de Visser, B. W., Cload, P., & Goudsmit, J. (1988). Decline of HIV antigen levels in cerebrospinal fluid during treatment with low-dose zidovudine. AIDS (London, England), 2(1), 37-40. https://doi.org/10.1097/00002030-198802000-00006

Vancouver

de Gans J, Lange JM, Derix MM, de Wolf F, Eeftinck Schattenkerk JK, Danner SA et al. Decline of HIV antigen levels in cerebrospinal fluid during treatment with low-dose zidovudine. AIDS (London, England). 1988;2(1):37-40. doi: 10.1097/00002030-198802000-00006

Author

de Gans, J. ; Lange, J. M. ; Derix, M. M. et al. / Decline of HIV antigen levels in cerebrospinal fluid during treatment with low-dose zidovudine. In: AIDS (London, England). 1988 ; Vol. 2, No. 1. pp. 37-40.

BibTeX

@article{402b24c12d564e3dbcd0cad52e96bceb,
title = "Decline of HIV antigen levels in cerebrospinal fluid during treatment with low-dose zidovudine",
abstract = "Six HIV-antigenaemic patients with AIDS or AIDS-related complex were studied to assess the effect of treatment with low-dose zidovudine (250 mg) in 6-hourly doses on HIV antigen (HIV-Ag) levels in cerebrospinal fluid (CSF). HIV-Ag was detected in CSF of three patients before treatment. These patients became CSF HIV-Ag-negative within 8 weeks of treatment. One initially CSF HIV-Ag-negative patient became strongly CSF HIV-Ag-positive during interruption of zidovudine treatment; CSF HIV-Ag disappeared again after treatment was restarted. None of our patients showed a significant neurological improvement during the study. These results show that low-dose zidovudine can suppress viral expression in CSF. Whether suppression of viral replication can prevent future HIV-related neurological disease remains to be investigated",
author = "{de Gans}, J. and Lange, {J. M.} and Derix, {M. M.} and {de Wolf}, F. and {Eeftinck Schattenkerk}, {J. K.} and Danner, {S. A.} and {Ongerboer de Visser}, {B. W.} and P. Cload and J. Goudsmit",
year = "1988",
doi = "10.1097/00002030-198802000-00006",
language = "English",
volume = "2",
pages = "37--40",
journal = "AIDS (London, England)",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

RIS

TY - JOUR

T1 - Decline of HIV antigen levels in cerebrospinal fluid during treatment with low-dose zidovudine

AU - de Gans, J.

AU - Lange, J. M.

AU - Derix, M. M.

AU - de Wolf, F.

AU - Eeftinck Schattenkerk, J. K.

AU - Danner, S. A.

AU - Ongerboer de Visser, B. W.

AU - Cload, P.

AU - Goudsmit, J.

PY - 1988

Y1 - 1988

N2 - Six HIV-antigenaemic patients with AIDS or AIDS-related complex were studied to assess the effect of treatment with low-dose zidovudine (250 mg) in 6-hourly doses on HIV antigen (HIV-Ag) levels in cerebrospinal fluid (CSF). HIV-Ag was detected in CSF of three patients before treatment. These patients became CSF HIV-Ag-negative within 8 weeks of treatment. One initially CSF HIV-Ag-negative patient became strongly CSF HIV-Ag-positive during interruption of zidovudine treatment; CSF HIV-Ag disappeared again after treatment was restarted. None of our patients showed a significant neurological improvement during the study. These results show that low-dose zidovudine can suppress viral expression in CSF. Whether suppression of viral replication can prevent future HIV-related neurological disease remains to be investigated

AB - Six HIV-antigenaemic patients with AIDS or AIDS-related complex were studied to assess the effect of treatment with low-dose zidovudine (250 mg) in 6-hourly doses on HIV antigen (HIV-Ag) levels in cerebrospinal fluid (CSF). HIV-Ag was detected in CSF of three patients before treatment. These patients became CSF HIV-Ag-negative within 8 weeks of treatment. One initially CSF HIV-Ag-negative patient became strongly CSF HIV-Ag-positive during interruption of zidovudine treatment; CSF HIV-Ag disappeared again after treatment was restarted. None of our patients showed a significant neurological improvement during the study. These results show that low-dose zidovudine can suppress viral expression in CSF. Whether suppression of viral replication can prevent future HIV-related neurological disease remains to be investigated

U2 - 10.1097/00002030-198802000-00006

DO - 10.1097/00002030-198802000-00006

M3 - Article

C2 - 3128994

VL - 2

SP - 37

EP - 40

JO - AIDS (London, England)

JF - AIDS (London, England)

SN - 0269-9370

IS - 1

ER -

ID: 2054410